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Abstract 
Weighing competing obligations and achieving the “greatest 
balance” of right over wrong guides an individual, an agency or 
a country in determining what ought to be done in an ethically 
challenging situation. Conducting controlled human infection 
model (CHIM) studies in India is one such situation. The ethical 
challenge in conducting a CHIM study lies in completing the 
difficult task of introducing standardised, attenuated strains of 
micro-organisms into normal healthy volunteers, at the same time 
ensuring the safety of these healthy individuals from potential 
and completely informed risks in a fashion that is transparent and 
accountable. The bar is further raised against the background of 
already fragile public confidence in biomedical research in India; 
especially when “deliberate” introduction of microbial agents into 
healthy individuals is involved, with the larger altruistic objective 
of gain to society as a whole. 
This paper discusses the uses of CHIM studies with respect to the 
larger scientific Indian research enterprise of the 21st century. It 
further explores etic and emic perspectives in conducting such 
trials in India and seeks to generate an ethical coherence to the 
justification for conducting CHIM studies in India. The paper 
deliberates on ethical issues arising out of conducting CHIM 
studies and reflects on how developing the capacity for CHIM 
studies in India is likely to strengthen the health research and 
development sector in the country. 
Introduction 
The strength of any country’s ethical research fabric lies in 
how and in what ways the scientific discourse benefits both 
the country’s public health and scientific advancement. 
Clinical trial operations in India are not in alignment with her 
healthcare needs and have swerved away from infectious 
diseases like tuberculosis and malaria  with an unfairly large 
proportion of registered trials focusing on non-communicable 
diseases like cancer and diabetes (1). This is despite the fact 
that the Global Burden of Disease Study for 2016 showed that 
communicable, maternal, neonatal and nutritional diseases 
(CMNNDs) contribute 24.8% of the overall disease burden 
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in India (2, 3). Infectious diseases in India have the highest 
Disability Adjusted Life Years (DALYs), but account for only 5% 
of the total clinical trials registered between July 2007 and 
December 2015.  Interestingly, a large proportion (46.6%)  of 
these trials were phase III trials and only 6.5% were phase I 
trials (4).
The skew towards phase III trials may understandably weaken 
the pace of scientific and technological enhancement of the 
Indian scientific enterprise; phase III trials are, after all,  trials 
which test already-tested drugs on a larger patient population, 
whereas phase I trials involve healthy human volunteers and 
hence require much more scientific expertise and ethical and 
regulatory preparedness (5). The safety of the participants who 
take part in these “first in man” studies is the combined social, 
moral and scientific responsibility of the research community. 
Is the Indian scientific-ethical research fabric strong enough 
to bear the responsibility of such trials? As of now, legal and 
regulatory requirements allow trials involving healthy human 
volunteers only for testing indigenously developed drugs and 
patents or foreign drugs which are already tested or are being 
concomitantly tested in healthy human volunteers elsewhere 
(6). Against this background, this essay argues the scientific 
and ethical merits of a specific trial design which involves 
the introduction of specially developed attenuated strains of 
microorganisms into healthy human volunteers. 
In order to understand the study design completely, the paper 
presents the definition and overview of a CHIM study design, 
discusses the uses of CHIM studies, and discusses the shift of 
focus from whether CHIM studies are ethically permitted or 
not, to CHIM studies being ethically required in India.
The paper goes on to present the inside (emic) and the outside 
(etic) perspectives on CHIM studies in India, and attempts to 
integrate both views to justify conducting CHIM studies in the 
country as a moral obligation, an ethical duty which is likely to 
benefit the public at large and the scientific community as a 
whole. 
Defining a CHIM trial: the what and how of a CHIM 
study design
This section summarises some of the scientific, technical, and 
community-related issues involved in a CHIM study.
A typical Controlled Human Infection study model is a phase 
I trial involving the intentional introduction of a pathogen of 
public health importance, a pathogen whose pathogenesis is 
well understood, and which is administered through a known 
and standard route in a specific dose; and which does not 
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cause any persistent infection or post-infection sequelae.Table 
1 summarises the characteristics of an ideal pathogen strain for 
a CHIM study(7-11),
Selection of subjects 
The well-standardised strain of pathogen in a CHIM study 
is introduced into carefully selected healthy, participant 
volunteers. These volunteers typically go through several 
stages of screening and are typically well-educated, well-
nourished, young, healthy individuals with normal immune 
systems. The recruitment process should be able to answer the 
questions mentioned in Table 2(12-15).
Safety considerations of participants 
Safety of the participant in a CHIM study is paramount and 
starts from the point of choosing the type of pathogenic strain 
used, to having stringent inclusion and exclusion criteria about 
volunteer participation, and rigorous screening measures for 
medical and psychological vulnerabilities. This can include a 
detailed vaccination history, review of past medical records and 
psychological assessments as per need. Table 3 summarises the 
Table 1: Characteristics of a typical Controlled Human Infection Model-Pathogen strain 
Characteristics of an ideal pathogen strain for CHIM study. Example of various pathogen strains used in CHIM studies. 
Needs to be of public health importance. 
P. Falciparum 3D7, NF54, and 7G8 strains, S. Typhi (quales strain), Noro 
virus strain G2.1, G2.2, G2.4, H.Pylori strain BCS100, Vibrio Cholera 01, Tor 
Inaba strain N16961, E.Coli expressed recombinant SERA-5(Honduras-1) 
for Malaria.
Pathogenesis of the strain is well understood, including incubation 
periods, course of illness, etc. 
Does not have or has an ineffective animal model. 
Does not have persistent infection or post-infection sequelae. The illness 
caused by the organism has to be either self limiting, reversible or have a 
standard effective treatment option. 
Has well defined definition of “infection” and “disease” and possibly has 
defined biomarkers for both. 
Has a standardised methodology of inoculum preparation, are mostly 
attenuated strains prepared under Good Manufacturing Practice (GMP)
guidelines and preservation which can be reproduced and disseminated.
Has a standard dose and a standard mode of administration and 
standard mode of assessment (screening test) of infection/disease.
Has predictable and measurable immune response and has well-defined 
immune, clinical and non-clinical end points which can be measured 
separately in the laboratory. 
Has known vectors which can be bred in controlled environments. 
Table 2: Volunteer screening and selection in a typical CHIM study design:
Questions Points for reflection on relevance to Indian settings
Is there fair selection of subjects? Social vulnerability in terms of poverty driving participation; 
Competence vulnerability in terms of ability to understand
Inherent vulnerabilities of language, cultural differences and 
Issues of family/individual consent.
Has the risk-benefit ratio been explained to and understood by the 
proposed volunteers? Has a personalised risk-benefit statement been 
made by the participant?
Open discussion on risks, discomfort, lack of direct benefit, purpose of 
enrollment, procedures involved including isolation (if involved), 
Concept of individual risk vs tangible social benefit from the trial, and
Degree of compensation for risk vs harm involved in participation.
Have efforts been made for community participation and engagement? Community sensitisation through focus group discussion platforms to 
build transparency and accountability. 
Has the participant undergone a fair informed consent process? Adequate process for clarifications, freedom for refusal to participate, 
confidentiality of information shared. 
various factors that need to be considered in order to ensure 
safety of the participants in a CHIM study(8,16-19).
Why use challenge studies? Scientific merit of CHIM 
models
Well-regulated challenge studies following universal scientific 
and ethical standards as described above have been a part of 
the scientific discourse of many countries for around 70 years 
now. More than 20,000 volunteers have taken part in around 
143 trials in developed countries and 12 in low- and middle-
income countries till date, and have contributed to answering 
important scientific and public health enquires as mentioned 
below:
1. To understand and evaluate transmission of infection
 CHIM study protocols have been developed to understand 
the transmission cycles of various pathogens inside the 
human body. A recent example is of a controlled human 
malaria infection model which studied gametocyte 
transmission of P falciparum from humans to mosquitoes.
This can have future implications in developing 
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Table 3: Factors to be considered in order to ensure participant safety in a CHIM study
Factors Salient points
Microbiological factors Choice of a strain with easily identifiable symptom profile and availability 
of prompt treatment, 
Separate and detectable microbial and clinical endpoints which can be 
easily monitored. 
Clear methods to confirm infection clearance or resolution.
Pathogen specific factors Using attenuated pathogen strains.
Using strains which are antibiotic sensitive and testing antibiotic 
sensitivity before the trial.
Setting specific factors Academic or commercial facilities which foster trust and have state-of-
the -art diagnostic investigation, transport and treatment pathways.
An adequate facility for isolation (if required) which provides 
environment for adequate physical and psychological well-being of 
participants and allows for prevention of spread of infection in the 
general community.
Participant specific factors Selected volunteers carefully screened for social, competence and 
individual vulnerabilities.
Well-informed participants who are at minimal risk of having incidental 
illnesses.
 If participant is from an endemic setting, consideration of environmental 
hygiene and sanitation infrastructure, vector circulation needs to be 
considered to ensure community safety. 
Regulatory factors A detailed independent review and oversight by a competent regulatory 
body which ensures monitoring of the trial at all stages
transmission-blocking interventions to prevent the spread 
of malaria (20). 
2. To understand pathogenesis or human immune response to 
various pathogens
 This is by far the most common use of challenge models. 
This is especially valuable for pathogens for which no 
suitable animal model exists. A good example would be the 
BCG human challenge model which provided important 
data on anti-mycobacterial immunity because of poorly 
understood animal data on immune responses to the same 
(21).
3. Use of CHIMs in vaccine studies
 There has been growing interest in using challenge 
strains of micro-organisms to study vaccine efficacy by 
administrating these strains at some point in time after 
vaccination. These are essentially proof of concept trials 
which eventually help to fast-track vaccine development 
by checking its efficacy on smaller numbers of human 
volunteers and prevent unnecessary exposure of 
thousands of people in larger Phase III trials. One good 
example of the same is how an Indian  Vi-tetanus toxoid 
conjugate vaccine developed by Bharat Biotech showed 
87% efficacy in protection against typhoid fever in a phase 
IIb randomised control study using a human challenge 
model by an Oxford Vaccine group in the United Kingdom 
(22, 23)
4. Use in vaccine screening
 Challenge models are used to assess potential vaccine 
candidates before subsequent stages of development of 
the vaccine. This essentially means helping researchers to 
up-select or down-select potential vaccine candidates and 
thereby avoids large scale, expensive field testing of these 
vaccines. Examples of this include the use of radiation 
attenuated malaria vaccine using plasmodium sporozoites 
which can induce sterilising immunity against challenge 
models of infectious sporozoites in human volunteers (24)
5. Use as therapeutic interventions
 Challenge models are used as direct therapeutic approach 
or aim to test the efficacy of a therapy after direct 
infection by a challenge strain. Examples of this include 
investigational therapeutics to treat shigellosis in various 
shigella flexneri models (25). 
6. Use in dose escalation studies
 Another area where challenge models are used is to 
determine challenge dosages needed to reach specific 
attack rates—example of this include salmonella typhi dose 
escalation studies in an ambulant model design to advance 
the understanding of host-pathogen interactions and 
immunity at different doses of exposure to salmonella typhi 
(26).
7. For study of various facets of infection and derived immunity 
in humans. 
 Human challenge studies are the most obvious way to 
prove causality. Unlike past self-challenge serendipitous 
discoveries, well regulated CHIM studies have been able to 
identify rhinovirus as the main cause behind the common 
cold. Another important area where CHIM studies have 
contributed is in knowing important virulence factors and 
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identifying mechanisms underlying host susceptibility. 
An example of this is the N. Gonorrhoae IgA1 protease 
deficient strain challenge model which attempts to assess 
its potential virulence in male volunteers (27).
 Does India need CHIM studies? Emic and etic 
perspectives
As is evident, CHIM studies are technically challenging and 
ethically demanding as they attempt to balance acceptable 
levels of risk to healthy human volunteers with a transparent 
and truly informed consent process. CHIM studies are also 
socially compelling as, though they do tend to answer 
questions of public health importance; they also demand 
community participation and sensitisation to the nebulous 
concept of risk-benefit ratios in research. 
So, does India need such ambitious projects at all? Can’t we do 
without them? Are CHIM studies a “want” or a “need” for Indian 
society? What is the social value of such studies in India? 
An ethical enquiry into the need for CHIM studies in India 
would require one to use both emic and etic perspectives to 
understand the relevance of such studies in the Indian cultural 
fabric. The subsequent sub-section weighs conflicting prima 
facie obligations using the reflective equilibrium approach 
(28) to reach a state of balance justifying the conduct of CHIM 
studies as a moral obligation. 
What is the Reflective Equilibrium approach?
Generating a coherent argument is central to moral 
justification. A principle, a theory or a judgement would 
become obligatory if (and only if ) it has gone through a 
process which allows pruning, matching and adjusting of 
what John Rawls called “considered judgments”. A considered 
judgement is one which is the starting point of an argument 
and is held with the highest confidence and with the least bias. 
For example, the moral axiom of “Research should benefit the 
participant” will start as a considered judgement in the design 
of a research proposal, However, this anchor will need to go 
through a process of specification and balancing; a process 
called reflective equilibrium to reach a state of harmony with 
the situation to render it coherent. In this example, the axiom 
will need to be made as coherent as possible with equally 
or more demanding considered judgements: the scientific 
need to pursue research, benefit to society, or respect for the 
autonomy to reject participation even if it is beneficial—      just 
to name a few. The idea is that irrespective of what is finally 
opted for, the maximum coherence of norms will always be a 
primary objective.
Using this method, the next sub-section argues within the emic 
and etic dimensions of the Indian research fabric for CHIM 
studies becoming an obligatory need
An emic perspective
CHIM studies, from an emic (from the inside) perspective of an 
average healthy participant volunteer, would arouse serious 
doubts about the Indian ethical research fabric which need 
to be explained and resolved in order to reach a reasonable 
reflective equilibrium. 
First and foremost, these studies challenge the established 
principle/considered judgement of primum non nocere—
“Above all, do no harm” and flood the average, informed Indian 
healthy volunteer’s mind with  appalling historical memories 
of unregulated scientific experiments performed by the Nazis, 
and the Tuskegee experiments on normal human subjects 
which would clearly be considered unethical today (29-30). The 
Indian research environment has seen turbulent times with 
reports of direct harm to uninformed vulnerable participants 
in the now infamous phase III trials conducted in Indore and 
Bhopal in 2004; and the human papillomavirus vaccine trials 
involving girls from tribal communities in Gujarat and Andhra 
Pradesh in 2010 (31-34).  
However, the argument which sharpens the established 
principle is that the starting point of a CHIM trial is a well-
informed, healthy, adult volunteer who has clearly understood 
the risks involved in participation and is carefully selected 
through a transparent and accountable informed consent 
process; and not an individual vulnerable on account of social, 
individual or competence vulnerabilities. A robust informed 
consent process is an absolute necessity but may not be a 
sufficient pre-requisite for any phase I trial. The participant in 
a CHIM trial is also someone who has understood the known, 
unknown and potential risks involved and again, the engaging 
point is not an ill-defined or general risk expression; it is a clear, 
unambiguous communication of defined risk with respect 
to the concerned CHIM model. And as Evans and Evans have 
put it—“when research is avowedly non-therapeutic, we 
could say that the risks are minimal if the research procedure 
involves no foreseeable harms which are either more likely or 
more severe, than those that one could meet in everyday life. 
It is expected that daily life, involves a certain amount of risk, 
after all”(29). Of course, a CHIM trial cannot be called “non-
therapeutic”, but the statement provides a reference point of 
what could be considered minimal risk and which trials can be 
considered too dangerous to participate in. “Minimal risk” in 
research is thus the amount of risk which is no more harmful 
than the risk entailed in certain activities that an individual 
voluntarily takes part in in everyday life. This standard, if taken 
as the minimum standard for any Indian participant, will ensure 
maximum protection of the participant entering any trial. 
This assessment of risk, if considered as reference standard, 
allows a dimensional and subjective degree of minimal risk 
that the participant can be lawfully helped to take in their own 
comparable areas of life. This is obviously unlike the stance 
that most guidelines take with respect to allowable risk in 
research. However, this does provide a dimensional aspect to 
the categorical and certainly narrower construct of primum non 
nocere and allows a higher moral justification to be reached 
from the participant’s point of view in case of CHIM trials.
Taking the sharpening process further—a well-informed 
healthy volunteer completely aware of the risks involved for 
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participation in CHIM studies in India might be a necessary 
pre-requisite but may not be sufficient to justify a CHIM trial in 
India. A research participant anywhere around the world would 
consider the social value of any research at par with, if not 
above, the scientific rigour of the research design.  Most of the 
diseases that challenge models investigate for pathogenesis, 
immunity, treatment or vaccines studies are endemic in 
India. From an emic perspective, CHIM studies in disease-
endemic settings like India provide a better understanding 
of genetics, pre-exposure, immune status and environmental 
factors that play a role in disease manifestation. The potential 
social benefits of generating evidence from a country’s own 
population and for the benefit of their own society make 
ethical, social and political sense. For example, it would have 
been much more ethically justifiable if the evidence of efficacy 
of the typhoid vaccine in the recently concluded phase IIb 
trial had been tested on consenting healthy volunteers in 
an Indian setting for two reasons: first, typhoid is endemic in 
India and the results would have been generalisable to the 
Indian population; and second, the CHIM strain of Typhoid 
vaccine (Vi-TT, typbar-TCV) was developed in India. The “Of the 
participant, By the experts-participants joint endeavour, For 
the participant” argument makes the ethical justification much 
more coherent, inclusive and adds weight to CHIM studies 
becoming an obligatory need from an emic perspective.
An etic perspective
From an etic (from the outside) perspective, an important 
established principle/considered judgement to begin with 
would be that involving distributive justice: given the dramatic 
inequalities in access and exorbitant increases in the costs 
of healthcare, would it be fair and equitable for the scientific 
diaspora to invest limited resources in demanding trials like 
CHIM in a resource-poor country like India? 
Premise of fundamental need
In order to answer this complex question—let us look into 
the concept of what constitutes a fundamental need.  A 
fundamental need would be one which, if not provided/
distributed according to need, could result in the individual 
or community suffering harm, or at least a detrimental effect. 
Though the need for CHIM studies from a scientific perspective 
is clear, as aiding scientific development, it becomes an ethical 
obligation only when it resonates with the concept of a 
fundamental need. 
Argument towards a CHIM study being a fundamental need
Using the reflective equilibrium approach, let us start with 
the established scientific principle that a controlled human 
infection model is beneficial for assessment of a preliminary 
vaccine or assessment of human immune response to a 
particular pathogen for a society which needs it. Suppose such 
a CHIM study is designed for a small population of healthy 
consenting volunteers and this shows that the candidate 
vaccine is ineffective; this in a way helps prevent a larger harm 
by avoiding the unnecessary exposure of thousands of people 
to large and costly phase III trials which would otherwise 
have to be designed to test its benefit. Having said this, it 
does not mean that human challenge trials are an alternative 
to phase III trials, they may help in licensing a product, which 
is then followed by strict post -marketing surveillance of the 
product—as is evident from the development of cholera 
vaccine Dukoral (35). Further, sharpening the established 
principle, using a CHIM design may prevent harm by avoiding 
exposure of the general population to vaccine candidates 
which are tested for efficacy in animal models, after all, animal 
models are often inadequate predictors of immune response. 
The etic perspective on the issue of conflicting fundamental needs
Thus, providing an opportunity to participate in a CHIM 
trial to a healthy, consenting volunteer in India becomes a 
fundamental need based on a double negative argument—
not providing such an opportunity may amount to possible 
harm. This is obviously a weak argument, chiefly because this 
fundamental need has to compete with larger and often 
unfulfilled needs like basic sanitation and provision of primary 
healthcare facilities to the Indian population. It is obvious that 
the latter may be considered a higher priority over the former 
in Indian society where healthcare lacks insurance support 
and is starkly unequal in distribution.  However, egalitarian 
principles of justice do further sharpen the original established 
principle with respect to CHIM studies: well equipped 
healthcare institutions should allow each person to achieve 
a fair share of the normal range of opportunities available in 
society. Among others, a CHIM trial is one such opportunity. 
Towards an integrated approach: Justifying CHIM 
studies in India
Thus, based on the reflective equilibrium approach which 
sharpens established principles and considered judgments, 
both emic and etic perspectives seem to justify the idea of a 
CHIM study for the Indian population. 
Justifying the act of conducting a CHIM study in India 
would require procedural justice and regulatory vigilance 
to be implemented at all steps of a CHIM study.  Developing 
adequate infrastructure and clinical services which allow 
volunteer participants to be engaged outside their home 
environment for a stipulated time period, establishing 
laboratory facilities and infrastructure requirements for 
developing and regulating delivery pathways to locally 
relevant strains of pathogens under Good Manufacturing 
Practices guidelines seems to be the first procedural step 
towards conducting CHIM studies in India. 
The second and equally important step would be to develop 
scientific rigour to structure protocols for a fair selection of 
participants and ensure a robust informed consent process. 
Community participation, transparent public engagement, 
assessment of motivation for participation and justified 
provision of compensation for the risk/harm for the participant 
provides a trust-building third step. 
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Finally, ensuring and implementing regulatory policies for the 
safety of the volunteers participating in CHIM studies in India 
can be achieved through a robust regulatory environment 
supported by law, which meets and enforces high regulatory 
standards of care provided to the participants. 
Challenges and recommendations 
Prima facie obligations and prima facie rights always prevail, 
unless a competing moral obligation or right can be shown to 
be overriding in particular circumstances. As Ross puts it, “the 
greatest balance” of right over wrong must be found (28). This 
bioethical enquiry into the need for CHIM studies through 
emic and etic perspectives, using reflective equilibrium, does 
generate coherence to justify conducting CHIM studies in India 
as a moral obligation.
Notwithstanding the compelling scientific and ethical merits 
of the argument, the moral sense of necessity motivating 
people to participate and to act to fulfil local needs, supported 
by provision of a transparent and strong regulatory platform 
to conduct CHIMs where all stake-holders’ interests are 
considered,with trust as a central ingredient in a common 
agenda to ensure safety of the participants remains the major 
challenge of this ethical discourse(36) 
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Abstract
Controlled human infection model studies, or challenge studies, 
involve the intentional infection of a consenting healthy human 
volunteer with a virulent organism under controlled conditions 
Such studies differ from clinical trials in that though both involve 
healthy volunteers, in challenge studies the potential harm 
experienced by participants is intended, not merely potentially 
foreseen, as in clinical trials. Given the special nature of CHIM 
studies, careful consideration of participant selection and 
compensation is essential. This paper explores the ethical criteria 
for recruiting participants in such studies, their own possible 
motivation such as monetary payment or access to treatment 
and how that should not amount to an inducement. It also 
distinguishes between compensation as inducement and fair 
compensation for the possible contracting of an illness, isolation, 
loss of work and adverse effects, and indicates that more research 
on the subject needs to be done.
Background
Controlled human infection model (CHIM) studies (or 
challenge studies) involve the intentional infection of a 
consenting healthy human volunteer with a virulent organism 
under controlled conditions. CHIM studies differ from clinical 
trials in some important aspects. While healthy volunteers are 
recruited for participation in both phase 1 clinical trials and 
challenge studies, the anticipation of harms is different. In 
challenge studies potential harm experienced by participants 
is intended, not merely potentially foreseen, as in clinical 
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trials that evaluate safety (1). The first report from participants 
in a malaria human challenge model in Kenya found that 
participants reported financial compensation as their major 
motivator for participation (2), which emphasises the special 
nature of ethical review and oversight of CHIM studies, 
requiring careful consideration of participant selection and 
compensation. However, the objectives of ethical review 
and oversight remain the same, and they are to ensure 
the wellbeing and prevention of exploitation of research 
participants (3).  
The memories of unethical research from the Nazi regime 
and other historical research where participants have been 
exploited have made some of the public suspicious of any type 
of medical research (4, 5).  These violations of ethics have made 
medical research the object of close scrutiny by the media, 
public and regulators, with violations paving the way for the 
development of guidelines, codes and regulations governing 
the conduct of research. However, even though CHIM studies 
have been conducted for several decades now outside of India, 
until recently there have been no ethical guidelines developed 
specifically for this type of research. 
In spite of the existence and use of guidelines, and scrutiny of 
studies by institutional review boards (IRBs), research has not 
been without controversies in India. Deviations from guidelines, 
both old and new, continue to make media headlines. In the 
light of this milieu, how can researchers ensure ethical conduct 
of CHIM studies, whose very design has the potential to arouse 
negative public opinion and media attention?  
An important ethical violation often highlighted is the criteria 
used for selection of participants in research.  Critiques 
have pointed out several deviations from ethical selection 
including deception during recruitment (5), poor consenting 
processes, and inadequate disclosure of risks, incentives and 
compensation clouding a potential participant’s judgement, 
subtle coercion, vulnerable participants being chosen for 
ease of conducting the study and to ensure consent (6) and 
so on.  Inadequate knowledge of participants’ motivation to 
